Clinical Trial Search

Primary: Prevalence of Vitamin B12 Deficiency — 3; 6; 4 participants

Primary: Change in Diffusion Capacity for Carbon Monoxide (DLco) From Baseline to 48 Weeks — 4; 2; 1 participants

Primary: Alteration of Microbiota, Alteration of T Cell Function/Activation — 4; 10; 2; 0 participants

Primary: Number of Participants With Grade 3 and 4 Toxicities of Administration of Oral Sirolimus — 1 participants

Primary: Incidence of Infusion Related Reactions With Rapid Infusion Will be Reported — 0; 0 infusion reactions

Primary: Left Ventricular Mass Indexed to BSA, g/m^2 — 43.8; 42.2 g/m^2

Primary: Presence of Conduction Disorders in Patients With SLE Regarding to Its Serologic Profile — 89.22; 91.41; 145.68; 146.72 msec

Primary: Slow Wave Sleep — 82.6; 67.3 Minutes

Primary: Number of Subjects With Lipids Checked (Available Now Through National Laboratory Chain) or That Reported Having Their Lipids Checked by Their 1-week or 3-month Visit…

Primary: Disease Activity Score Based on 28-joint Disease Activity Score (DAS28) — 4.40; 4.03; 4.57; 4.48 units on a scale

Primary: Change From Baseline in Distance Walked During a Six Minute Walk Test — 23.6; 0.5 Meters — p=0.12

Primary: 12 Month Change in 7-Joint Ultrasound (US) Inflammatory Score — 11.4 units on a scale — p=<0.01

Primary: RADAI Disease Activity Score — -0.4; 0.1 units on a scale — p=0.04

Primary: Percentage of Participants Achieving DAS28 Remission. — 6; 6 Participants — p=0.530

Primary: Intervention Feasibility as Measured by Number of Providers Agreeing to Participate — 6 Participants

Primary: Number of Participants Diagnosed With Rheumatoid Arthritis Also Found to Have Dry Eye Disease — 275 participants

Primary: Flow-mediated Vasodilation (FMD) — 6.1; 4.4 percentage change in diameter

Primary: Reduction of the Disease Activity as Measured by SLEDAI and BILAG Scores. — 10.2; 28.4 score on a scale

Primary: Percentage of CD27+ Switched Memory B Cells at Week 12 — 13.2; 13.8 Percentage of B Cells — p=0.3

Primary: CDAI Score — 36.06 score on a scale

Primary: Mean 48-week Change in DAS28 — -2.12; -2.29 units on a scale

Primary: DAS28-ESR — 3.75; 3.72; 3.59; 3.69 units on a scale — p=0.82

Primary: IL-7 and IL-7R Expression in Peripheral Blood Mononuclear Cells of RA Patients With Active vs. Inactive Disease Treated With DMARD and/or CIMZIA. — 0.700; 1.330; 0.777…

Primary: Event Rate for a Cardiovascular Composite of Incident Myocardial Infarction, Stroke, or Heart Failure — 10.62; 8.13 Events per 1000 person years

Primary: Percentage of Participants Achieving American College of Rheumatology Score 20 Percent (ACR20) Response — 63.46; 76.15 Percentage of participants

Primary: Disease Activity — 3.38; 3.62 score on a scale

Primary: Comparison Between the Time to Improvement Between the Two Groups of IIM (Idiopathic Inflammatory Myopathy) Patients — 20.2; 20.0 Weeks — p==0.74

Primary: Physician Global Assessment of Disease Activity — 21; 14; 12; 43 mm

Primary: Autoantibodies to Human Epidermoid (HEp)-2 Cells — 288; 177 titer

Primary: Hospital Anxiety and Depression Scale (HADS) — 107; 46; 20; 27 participants